FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy
On March 1, 2024, the U.S. FDA approved RYBREVANT in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR ...
Are GLP-1 supplements 'nature's Ozempic'? Doctors evaluate weight loss claims
GLP-1 supplements are advertised as a cheaper alternative to weight loss with Ozempic or Wegovy. Doctors explain if they help ...
The Lancet23m
Divisions over lecanemab: keeping an open mind
After more than a century since Alois Alzheimer's description of an “unusual illness of the cerebral cortex”, the development ...
Stockhead on MSN27m
Top 10 at 11: Silver takes the lead, but a cancer-drug competitor is also running hard
Stockhead’s Top 10 at 11 is a short, sharp update to help frame the trading day. ... Read More The post Top 10 at 11: Silver ...
Poison Control centers see spike in calls about young people drinking energy drinks
America’s Poison Centers reports a 20% increase in calls to centers across the country about young people drinking energy ...
The Lancet23m
The promise of once-weekly insulins for type 1 diabetes: update on progress
For people with type 1 diabetes, management burden including suboptimal insulin preparations remains a major barrier to ...